ABBV

AbbVie (ABBV)

AbbVie Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:ABBV

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/09/25	20:00	PR Newswire (US)	New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement	NYSE:ABBV	AbbVie Inc
2024/09/24	21:00	PR Newswire (US)	Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns	NYSE:ABBV	AbbVie Inc
2024/09/20	20:32	PR Newswire (US)	AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer	NYSE:ABBV	AbbVie Inc
2024/09/11	21:30	PR Newswire (US)	Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China	NYSE:ABBV	AbbVie Inc
2024/09/11	04:30	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ABBV	AbbVie Inc
2024/09/10	20:00	PR Newswire (Canada)	Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age	NYSE:ABBV	AbbVie Inc
2024/09/10	20:00	PR Newswire (Canada)	AbbVie reçoit l'approbation de Santé Canada pour l'emploi de CONSTELLA® (linaclotide) dans le traitement de la constipation fonctionnelle chez les enfants âgés de 6 à 17 ans	NYSE:ABBV	AbbVie Inc
2024/09/09	22:00	PR Newswire (US)	AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs	NYSE:ABBV	AbbVie Inc
2024/09/06	23:13	PR Newswire (US)	AbbVie Declares Quarterly Dividend	NYSE:ABBV	AbbVie Inc
2024/09/04	21:00	PR Newswire (Canada)	AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénie	NYSE:ABBV	AbbVie Inc
2024/09/04	21:00	PR Newswire (Canada)	AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia	NYSE:ABBV	AbbVie Inc
2024/08/27	21:15	PR Newswire (US)	AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases	NYSE:ABBV	AbbVie Inc
2024/08/27	21:05	PR Newswire (US)	SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator	NYSE:ABBV	AbbVie Inc
2024/08/20	03:05	PR Newswire (US)	European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	NYSE:ABBV	AbbVie Inc
2024/08/15	22:14	PR Newswire (Canada)	AbbVie annonce les premiers remboursements provinciaux, en Ontario et au Québec, d'EPKINLY(MC) (epcoritamab) administré par voie sous-cutanée pour le traitement du lymphome diffus à grandes cellules B en vertu d'un nouveau processus d'accès rapide	NYSE:ABBV	AbbVie Inc
2024/08/15	22:13	PR Newswire (Canada)	AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process	NYSE:ABBV	AbbVie Inc
2024/08/15	05:09	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:ABBV	AbbVie Inc
2024/08/09	06:40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:ABBV	AbbVie Inc
2024/08/08	05:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:ABBV	AbbVie Inc
2024/08/08	04:00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:ABBV	AbbVie Inc
2024/08/01	21:23	PR Newswire (US)	AbbVie Completes Acquisition of Cerevel Therapeutics	NYSE:ABBV	AbbVie Inc
2024/07/30	21:00	PR Newswire (US)	Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day	NYSE:ABBV	AbbVie Inc
2024/07/30	19:00	IH Market News	Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots	NYSE:ABBV	AbbVie Inc
2024/07/28	21:05	GlobeNewswire Inc.	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)	NYSE:ABBV	AbbVie Inc
2024/07/26	15:00	PR Newswire (US)	AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	NYSE:ABBV	AbbVie Inc
2024/07/25	20:41	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:ABBV	AbbVie Inc
2024/07/25	20:36	PR Newswire (US)	AbbVie Reports Second-Quarter 2024 Financial Results	NYSE:ABBV	AbbVie Inc
2024/07/25	19:21	IH Market News	U.S. Index Futures Mixed After Tech Sell-Off, Oil Prices Drop on Weak China Demand and Ceasefire Expectations	NYSE:ABBV	AbbVie Inc
2024/07/23	20:02	PR Newswire (Canada)	AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency	NYSE:ABBV	AbbVie Inc
2024/07/23	20:02	PR Newswire (Canada)	L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC)	NYSE:ABBV	AbbVie Inc